Telix Pharmaceuticals Ltd (STU:T3X)
€ 14.8 0.49 (3.42%) Market Cap: 4.90 Bil Enterprise Value: 4.84 Bil PE Ratio: 162.08 PB Ratio: 19.98 GF Score: 75/100

Telix Pharmaceuticals Ltd at Jefferies London Healthcare Conference Transcript

Nov 17, 2022 / 03:15PM GMT
Dave Stanton
Jefferies LLC - Analyst

Good afternoon, everyone. Welcome to another afternoon session of the Jefferies London Healthcare Conference. My name is Dave Stanton. I'm part of the Jefferies Australia healthcare research team. It's my absolute pleasure to be hosting Telix today. And Dr. Chris Behrenbruch, CEO of Telix, is with us.

We thought we'd start with a presentation, get everybody up to date on the company. And then it's a chat after that. So if anybody has got any questions, please raise your hand and it will either be a microphone come around or you can just repeat the question back to me.

Chris, thanks very much, and over to you.

Chris Behrenbruch
Telix Pharmaceuticals Limited - MD, CEO

Yeah, thanks, Dave. Really appreciate it, and thanks to the Jefferies team for the opportunity to present to you today. I'm just going to give a few introductory slides. We're not a super widely known company yet. So it's an opportunity for me to give you a bit of background.

We are a radiopharmaceutical company, one of the leading

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot